Streetbeat News

Stock Prices

VTYX

Ventyx Biosciences announced that its Phase 2 trial of VTX958 did not meet the primary endpoint in patients with moderately to severely active Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:02 pm

CTVA

Corteva, Inc. (NYSE:CTVA) announced an increase in its quarterly dividend from $0.16 to $0.17 per share, representing an annual increase of over 6%. The dividend is payable on September 17, 2024, to shareholders of record on September 3, 2024. This marks the fourth dividend increase since Corteva's 2019 spin-off, highlighting the company's focus on margin expansion, sustainable growth, and returning capital to shareholders.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:01 pm

AVTR

In the last three months, 5 analysts have published ratings on Avantor (NYSE:AVTR), with a mix of bullish and bearish perspectives. The average 12-month price target is now $26.6, down from $28.40. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Avantor has faced a 5.65% decline in revenue over the past three months but maintains strong net margins, ROE, and ROA. However, it struggles with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 12:01 pm

SLP

Analysts' ratings for Simulations Plus (NASDAQ:SLP) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $56.0, with a high estimate of $65.00 and a low estimate of $47.00. Key analysts from firms like Keybanc, Craig-Hallum, and Oppenheimer have provided updated ratings and price targets, reflecting positive market dynamics and company performance. Simulations Plus has shown strong financial health with notable revenue growth, net margin, ROE, and ROA, and maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 12:01 pm

TER

Analysts have shared mixed opinions on Teradyne (NASDAQ:TER) over the past three months, with a range of ratings from bullish to bearish. The average 12-month price target has increased to $156.58, reflecting a 15.49% rise. Teradyne has shown strong financial performance with significant revenue growth, high net margins, and effective debt management.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 12:00 pm

CTRI

Centuri Holdings shares have been halted pending news. Investors are awaiting further information that could impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:59 am

CGTX

Cognition Therapeutics announced that in the SHINE study, their drug CT1812 did not achieve statistical significance on the first of the ordered secondary efficacy endpoints in the pooled 100mg and 300mg dose group compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:58 am

VTYX

Trading for VTYX was halted at 7:55:00 a.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:55 am

BMR

NVDA

ORCL

Beamr Imaging Ltd. (NASDAQ:BMR) will demonstrate optimized 3D design video rendering using Oracle Cloud Infrastructure (OCI) and Nvidia accelerated computing at SIGGRAPH 2024. The demonstration will showcase reducing large video files to one-fourth of their original size.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:50 am

BLK

BTCUSD

ETHUSD

Kamala Harris is not favored by the crypto community, while Donald Trump is seen as a pro-crypto candidate. Trump attended the Bitcoin Conference and expressed support for Bitcoin and the crypto market. The SEC has softened its stance on crypto, and new Ethereum ETFs have been launched. Bitcoin is trading above key moving averages, indicating bullish sentiment.

Portfolio Pulse from Kenneth Rapoza

July 29, 2024 | 11:48 am